Abivax: presentation on obefazimod at the ECCO congress
The ECCO congress provides us with an excellent platform to present our new data and continue to raise awareness of obefazimod's unique mechanism of action", comments Sheldon Sloan, Abivax's Medical Director.
According to the biopharmaceutical company, data on its lead drug candidate "indicate that it exerts its anti-inflammatory activity by stabilizing the immune response in patients with ulcerative colitis".
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction